Study of a Potential Test for Persistent Lyme Disease
Thanks to the enthusiastic response from the Lyme community, this study has met its current enrollment goal. Therefore, Flightpath Biosciences’ Study of a Potential Test for Persistent Lyme Disease will not be accepting any more applications at this time.
We’ll keep you posted as the project proceeds or if we reopen the study for further enrollment.
For questions related to this study, please contact: FlightpathLymeStudy@gmail.com
Fatigue, muscles aches, brain fog—are these symptoms of chronic Lyme disease, or merely side effects of the daily grind of human existence? It’s hard to tell.
Chronic Lyme disease, also known as post-treatment Lyme disease syndrome or PTLDS, is incredibly hard to diagnose because symptoms vary greatly, and there is currently no biological test to detect the disease.
Now, Kim Lewis, University Distinguished Professor of biology and director of the Antimicrobial Discovery Center at Northeastern, has proposed a new way to objectively diagnose this elusive disease by analyzing the microbes in a patient’s gut.
(Go to link for article)
Lewis states there are about 800,000 people in America living with PTLDS. I have written before about this confusing moniker that it means different things to different people. For instance, microbiologist Holly Ahern states there are two groups of patients: those diagnosed and treated early and those diagnosed and treated late. The PTLDS label only concerns the first group and only represents about 10-20% of people going on with persistent symptoms. These low percentages are typically what researchers are referring to. The label leaves out a much larger group (30-40%) that is diagnosed and treated late.
This second group represents nearly all the patients I work with that never gets addressed by research because their cases are sticky, hard to define, and by nature don’t fit well into a research study design.
According to Lewis, people with PTLDS have an abundance of a type of bacteria called Blautia and a suppression of a type of bacteria called Bacteroides (which explains why Lyme/MSIDS patients suffer with inflammation, digestion, improper immune responses, depression and anxiety).
Unfortunately, this bacterial disregulation is also seen in many other diseases.
Flightpath is also working on making an oral form of the antibiotic azlollicin available, which has demonstrated in vivo efficacy in mice by significantly inhibiting the growth of drug-tolerant Borrelia burgdorferi (Bb) bacteria better than doxycycline (the standard of care), and reducing inflammation.